Spots Global Cancer Trial Database for azd6738
Every month we try and update this database with for azd6738 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial | NCT03182634 | Advanced Breast... | Fulvestrant Neratinib AZD5363 Olaparib AZD6738 | 18 Years - | Institute of Cancer Research, United Kingdom | |
| PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer | NCT03740893 | Breast Neoplasm | AZD6738 Olaparib Durvalumab | 18 Years - | Institute of Cancer Research, United Kingdom | |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | NCT02664935 | Non-Small Cell ... Carcinoma, Squa... Adenocarcinoma | AZD4547 Vistusertib Palbociclib Crizotinib Selumetinib Docetaxel AZD5363 Osimertinib Durvalumab Sitravatinib AZD6738 | 18 Years - | University of Birmingham | |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | NCT02664935 | Non-Small Cell ... Carcinoma, Squa... Adenocarcinoma | AZD4547 Vistusertib Palbociclib Crizotinib Selumetinib Docetaxel AZD5363 Osimertinib Durvalumab Sitravatinib AZD6738 | 18 Years - | University of Birmingham | |
| This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO) | NCT03780608 | Gastric Adenoca... Malignant Melan... | AZD6738 Durvalumab | 19 Years - | Samsung Medical Center | |
| AZD6738 for Patients With Progressive MDS or CMML | NCT03770429 | Leukemia Myelodysplastic... | AZD6738 | 18 Years - | Massachusetts General Hospital | |
| OLAParib COmbinations | NCT02576444 | Cancer | AZD2281 AZD5363 AZD1775 AZD6738 | 18 Years - | Yale University | |
| AZD6738 Plus Durvalumab in Biliary Tract Cancer | NCT04298008 | Bile Duct Cance... Chemotherapy Ef... | AZD6738 Durvalumab | 20 Years - | Seoul National University Hospital | |
| Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer | NCT03462342 | High Grade Sero... | Olaparib Pill AZD6738 | 18 Years - | University of Pennsylvania | |
| AZD6738 & Gemcitabine as Combination Therapy | NCT03669601 | Cancer | AZD6738 Gemcitabine | 16 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| AZD6738 for Patients With Progressive MDS or CMML | NCT03770429 | Leukemia Myelodysplastic... | AZD6738 | 18 Years - | Massachusetts General Hospital | |
| OLAParib COmbinations | NCT02576444 | Cancer | AZD2281 AZD5363 AZD1775 AZD6738 | 18 Years - | Yale University | |
| AZD6738 & Gemcitabine as Combination Therapy | NCT03669601 | Cancer | AZD6738 Gemcitabine | 16 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| AZD6738 & Gemcitabine as Combination Therapy | NCT03669601 | Cancer | AZD6738 Gemcitabine | 16 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss | NCT04065269 | Gynaecological ... | AZD6738 Olaparib | 18 Years - | Institute of Cancer Research, United Kingdom | |
| Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2] | NCT03428607 | SCLC | AZD6738 Olaparib | 20 Years - | Samsung Medical Center | |
| Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial) | NCT03787680 | Prostate Cancer | Olaparib AZD6738 | 18 Years - | University of Michigan Rogel Cancer Center | |
| Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer | NCT02630199 | Refractory Canc... | AZD6738 Paclitaxel | 19 Years - | Samsung Medical Center | |
| DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer | NCT04298021 | Bile Duct Cance... Chemotherapy Ef... | AZD6738 Durvalumab Olaparib | 20 Years - | Seoul National University Hospital | |
| AZD6738 Plus Durvalumab in Biliary Tract Cancer | NCT04298008 | Bile Duct Cance... Chemotherapy Ef... | AZD6738 Durvalumab | 20 Years - | Seoul National University Hospital | |
| This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO) | NCT03780608 | Gastric Adenoca... Malignant Melan... | AZD6738 Durvalumab | 19 Years - | Samsung Medical Center | |
| AZD6738 for Patients With Progressive MDS or CMML | NCT03770429 | Leukemia Myelodysplastic... | AZD6738 | 18 Years - | Massachusetts General Hospital | |
| Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) | NCT03527147 | NHL DLBCL Non-hodgkin's L... Diffuse Large B... | AZD9150 Acalabrutinib AZD6738 Hu5F9-G4 Rituximab AZD5153 | 18 Years - 130 Years | Acerta Pharma BV |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
